| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urology | 33 | 2023 | 399 | 12.280 |
Why?
|
| Testosterone | 15 | 2022 | 2419 | 3.070 |
Why?
|
| Prostatic Neoplasms | 58 | 2024 | 11126 | 3.000 |
Why?
|
| Urologic Diseases | 10 | 2020 | 244 | 2.780 |
Why?
|
| Penile Neoplasms | 10 | 2018 | 161 | 2.620 |
Why?
|
| Urinary Bladder Neoplasms | 23 | 2020 | 2249 | 2.330 |
Why?
|
| Prostatic Hyperplasia | 8 | 2022 | 523 | 2.000 |
Why?
|
| Prostatectomy | 22 | 2022 | 1890 | 1.880 |
Why?
|
| Urologic Surgical Procedures | 4 | 2022 | 302 | 1.690 |
Why?
|
| Urologic Neoplasms | 6 | 2020 | 318 | 1.680 |
Why?
|
| BCG Vaccine | 4 | 2014 | 369 | 1.360 |
Why?
|
| Nephrectomy | 10 | 2020 | 1050 | 1.300 |
Why?
|
| Politics | 5 | 2022 | 791 | 1.250 |
Why?
|
| Famous Persons | 4 | 2016 | 108 | 1.230 |
Why?
|
| Prostate-Specific Antigen | 18 | 2024 | 2494 | 1.020 |
Why?
|
| Urinary Incontinence, Stress | 10 | 2000 | 183 | 0.990 |
Why?
|
| Kidney Neoplasms | 20 | 2023 | 4262 | 0.970 |
Why?
|
| Infertility, Male | 9 | 2013 | 409 | 0.930 |
Why?
|
| Equidae | 1 | 2023 | 10 | 0.930 |
Why?
|
| Urinary Bladder | 10 | 2020 | 1173 | 0.920 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2023 | 151 | 0.790 |
Why?
|
| Humans | 252 | 2024 | 744376 | 0.790 |
Why?
|
| Spermatozoa | 13 | 1997 | 625 | 0.780 |
Why?
|
| Medical Oncology | 6 | 2021 | 2267 | 0.770 |
Why?
|
| Malpractice | 5 | 2011 | 572 | 0.760 |
Why?
|
| Carcinoma, Renal Cell | 14 | 2023 | 3143 | 0.740 |
Why?
|
| Digital Rectal Examination | 2 | 2018 | 42 | 0.740 |
Why?
|
| Finasteride | 1 | 2021 | 90 | 0.730 |
Why?
|
| Physician Executives | 1 | 2021 | 128 | 0.720 |
Why?
|
| Nobel Prize | 1 | 2020 | 49 | 0.710 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2021 | 107 | 0.710 |
Why?
|
| Testicular Neoplasms | 11 | 2011 | 806 | 0.700 |
Why?
|
| History, 20th Century | 12 | 2022 | 2740 | 0.700 |
Why?
|
| Hypogonadism | 4 | 2016 | 799 | 0.670 |
Why?
|
| Ureteral Obstruction | 5 | 2007 | 296 | 0.670 |
Why?
|
| Catheterization | 2 | 2024 | 1470 | 0.670 |
Why?
|
| Global Warming | 1 | 2019 | 64 | 0.660 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2020 | 106 | 0.650 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2018 | 77 | 0.650 |
Why?
|
| Climate | 1 | 2019 | 147 | 0.650 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2021 | 360 | 0.630 |
Why?
|
| Science | 1 | 2021 | 241 | 0.630 |
Why?
|
| Hormone Replacement Therapy | 3 | 2016 | 745 | 0.620 |
Why?
|
| Male | 161 | 2024 | 350118 | 0.620 |
Why?
|
| Self Concept | 1 | 2024 | 1025 | 0.620 |
Why?
|
| Physicians | 3 | 2022 | 4567 | 0.620 |
Why?
|
| Happiness | 1 | 2019 | 170 | 0.610 |
Why?
|
| Laser Therapy | 4 | 2018 | 1072 | 0.590 |
Why?
|
| Alopecia | 1 | 2021 | 382 | 0.580 |
Why?
|
| Leadership | 2 | 2021 | 1357 | 0.580 |
Why?
|
| Homicide | 2 | 2014 | 287 | 0.570 |
Why?
|
| Nocturia | 2 | 2016 | 19 | 0.570 |
Why?
|
| Genital Diseases, Male | 4 | 2011 | 84 | 0.570 |
Why?
|
| Urogenital Neoplasms | 3 | 2012 | 137 | 0.570 |
Why?
|
| Carcinoma, Transitional Cell | 8 | 2015 | 808 | 0.560 |
Why?
|
| Prostate | 7 | 2024 | 1775 | 0.550 |
Why?
|
| Semen | 6 | 1997 | 316 | 0.550 |
Why?
|
| Urography | 4 | 2007 | 313 | 0.550 |
Why?
|
| Anatomy, Artistic | 2 | 2006 | 52 | 0.540 |
Why?
|
| Federal Government | 2 | 2009 | 260 | 0.540 |
Why?
|
| Penis | 6 | 2018 | 217 | 0.520 |
Why?
|
| Medical Illustration | 2 | 2006 | 133 | 0.520 |
Why?
|
| Professional Practice | 2 | 2015 | 326 | 0.510 |
Why?
|
| Lymph Node Excision | 8 | 2014 | 1261 | 0.500 |
Why?
|
| Specialties, Surgical | 1 | 2019 | 391 | 0.500 |
Why?
|
| Specialization | 1 | 2019 | 776 | 0.500 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2018 | 4034 | 0.490 |
Why?
|
| Watchful Waiting | 1 | 2018 | 492 | 0.490 |
Why?
|
| SEER Program | 2 | 2012 | 1507 | 0.480 |
Why?
|
| Antigens, Surface | 1 | 2018 | 1663 | 0.480 |
Why?
|
| Laparoscopes | 4 | 1996 | 41 | 0.470 |
Why?
|
| Urinary Incontinence | 4 | 2010 | 496 | 0.470 |
Why?
|
| Physician's Role | 1 | 2021 | 943 | 0.470 |
Why?
|
| Career Choice | 2 | 2018 | 744 | 0.470 |
Why?
|
| Health Care Costs | 4 | 2015 | 3209 | 0.460 |
Why?
|
| Urinary Calculi | 4 | 2002 | 91 | 0.460 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2016 | 415 | 0.460 |
Why?
|
| Testicular Hydrocele | 1 | 2013 | 28 | 0.450 |
Why?
|
| United States | 29 | 2022 | 69869 | 0.450 |
Why?
|
| Sperm Motility | 10 | 1994 | 253 | 0.450 |
Why?
|
| History, 19th Century | 4 | 2021 | 720 | 0.440 |
Why?
|
| Robotics | 1 | 2020 | 899 | 0.440 |
Why?
|
| Kallikreins | 1 | 2014 | 258 | 0.430 |
Why?
|
| Calcium Channels, L-Type | 1 | 2014 | 240 | 0.430 |
Why?
|
| Suction | 2 | 2013 | 267 | 0.430 |
Why?
|
| Telecommunications | 1 | 2013 | 80 | 0.430 |
Why?
|
| Anxiety Disorders | 1 | 2024 | 2690 | 0.420 |
Why?
|
| Immunotherapy | 3 | 2020 | 4445 | 0.420 |
Why?
|
| Exercise Therapy | 1 | 2019 | 904 | 0.420 |
Why?
|
| Ureter | 5 | 2001 | 375 | 0.410 |
Why?
|
| Biopsy | 4 | 2020 | 6755 | 0.410 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 941 | 0.410 |
Why?
|
| Sclerotherapy | 1 | 2013 | 175 | 0.410 |
Why?
|
| Vena Cava, Inferior | 2 | 2011 | 440 | 0.410 |
Why?
|
| Financial Support | 1 | 2012 | 115 | 0.400 |
Why?
|
| Androgens | 2 | 2016 | 1281 | 0.400 |
Why?
|
| Interferon-alpha | 2 | 2013 | 895 | 0.400 |
Why?
|
| Health Care Reform | 1 | 2021 | 1261 | 0.400 |
Why?
|
| Receptors, Androgen | 2 | 2016 | 1058 | 0.400 |
Why?
|
| Doxycycline | 1 | 2013 | 326 | 0.390 |
Why?
|
| Fibrin Tissue Adhesive | 2 | 2006 | 85 | 0.390 |
Why?
|
| Reactive Oxygen Species | 5 | 1997 | 2076 | 0.390 |
Why?
|
| Immunologic Factors | 1 | 2020 | 1580 | 0.390 |
Why?
|
| Cryptorchidism | 1 | 2011 | 125 | 0.380 |
Why?
|
| Vasovasostomy | 3 | 1999 | 6 | 0.370 |
Why?
|
| Epididymis | 2 | 2011 | 227 | 0.370 |
Why?
|
| Burnout, Professional | 1 | 2019 | 694 | 0.370 |
Why?
|
| Truth Disclosure | 2 | 2009 | 436 | 0.360 |
Why?
|
| Government | 3 | 2002 | 165 | 0.350 |
Why?
|
| Granuloma | 2 | 2011 | 319 | 0.350 |
Why?
|
| Urethra | 7 | 2002 | 408 | 0.350 |
Why?
|
| History, 21st Century | 4 | 2022 | 1534 | 0.350 |
Why?
|
| Prostatitis | 2 | 2008 | 102 | 0.340 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2014 | 8432 | 0.340 |
Why?
|
| Testis | 6 | 2013 | 804 | 0.340 |
Why?
|
| Endoscopes | 3 | 2005 | 175 | 0.340 |
Why?
|
| Cystectomy | 3 | 2020 | 686 | 0.330 |
Why?
|
| Motor Activity | 1 | 2019 | 2715 | 0.330 |
Why?
|
| Ureteral Calculi | 3 | 1998 | 110 | 0.330 |
Why?
|
| Inpatients | 1 | 2020 | 2518 | 0.320 |
Why?
|
| Wounds, Gunshot | 1 | 2014 | 563 | 0.320 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2009 | 198 | 0.320 |
Why?
|
| Insurance, Liability | 1 | 2008 | 102 | 0.310 |
Why?
|
| Transcriptional Activation | 1 | 2014 | 1783 | 0.310 |
Why?
|
| Germinoma | 2 | 2000 | 134 | 0.310 |
Why?
|
| Administration, Intravesical | 4 | 2014 | 91 | 0.300 |
Why?
|
| Adenocarcinoma | 9 | 2016 | 6364 | 0.300 |
Why?
|
| Inguinal Canal | 2 | 2006 | 69 | 0.300 |
Why?
|
| Scrotum | 4 | 1997 | 115 | 0.290 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2011 | 482 | 0.290 |
Why?
|
| Health Status | 3 | 2009 | 4033 | 0.290 |
Why?
|
| Laparoscopy | 5 | 2022 | 2150 | 0.290 |
Why?
|
| Pregnancy Complications | 6 | 2004 | 2861 | 0.290 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2014 | 9240 | 0.290 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 2213 | 0.290 |
Why?
|
| Varicocele | 3 | 1999 | 78 | 0.290 |
Why?
|
| Membranes, Artificial | 3 | 1994 | 378 | 0.290 |
Why?
|
| Salvage Therapy | 1 | 2013 | 1275 | 0.290 |
Why?
|
| Kidney Calculi | 3 | 2004 | 465 | 0.290 |
Why?
|
| Acrosin | 4 | 1994 | 5 | 0.270 |
Why?
|
| Prostatic Diseases | 2 | 2001 | 56 | 0.270 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2006 | 75 | 0.270 |
Why?
|
| Thrombectomy | 1 | 2011 | 680 | 0.270 |
Why?
|
| Erectile Dysfunction | 4 | 1998 | 461 | 0.270 |
Why?
|
| Delivery of Health Care | 3 | 2011 | 5321 | 0.270 |
Why?
|
| Suture Techniques | 5 | 1995 | 798 | 0.270 |
Why?
|
| Pediatrics | 1 | 2020 | 3475 | 0.260 |
Why?
|
| Diagnostic Imaging | 3 | 2015 | 3508 | 0.260 |
Why?
|
| Chromosome Aberrations | 2 | 2011 | 1813 | 0.260 |
Why?
|
| Hemostatics | 2 | 2006 | 229 | 0.260 |
Why?
|
| Tissue Adhesives | 1 | 2006 | 179 | 0.260 |
Why?
|
| Filtration | 4 | 1994 | 234 | 0.250 |
Why?
|
| Pelvic Neoplasms | 2 | 2005 | 254 | 0.250 |
Why?
|
| Canada | 2 | 2021 | 2065 | 0.250 |
Why?
|
| Adrenal Gland Diseases | 1 | 2005 | 138 | 0.240 |
Why?
|
| Employment | 1 | 2011 | 1132 | 0.240 |
Why?
|
| Pregnancy Complications, Neoplastic | 3 | 1995 | 255 | 0.240 |
Why?
|
| Circadian Rhythm | 1 | 2016 | 2624 | 0.240 |
Why?
|
| Acid Phosphatase | 1 | 2024 | 143 | 0.240 |
Why?
|
| Surgical Flaps | 5 | 2001 | 1640 | 0.240 |
Why?
|
| Prostheses and Implants | 3 | 2002 | 1387 | 0.230 |
Why?
|
| Mental Competency | 1 | 2005 | 176 | 0.230 |
Why?
|
| Vagina | 4 | 2002 | 825 | 0.230 |
Why?
|
| Endoscopy | 4 | 2022 | 1787 | 0.220 |
Why?
|
| Quality of Life | 4 | 2021 | 12803 | 0.220 |
Why?
|
| Sperm-Ovum Interactions | 3 | 1994 | 24 | 0.220 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2009 | 1115 | 0.220 |
Why?
|
| Emergency Medical Services | 1 | 2014 | 1917 | 0.210 |
Why?
|
| Patient Compliance | 1 | 2013 | 2685 | 0.210 |
Why?
|
| Biocompatible Materials | 2 | 2002 | 1736 | 0.210 |
Why?
|
| Back Injuries | 1 | 2002 | 40 | 0.210 |
Why?
|
| Pheochromocytoma | 4 | 2007 | 337 | 0.210 |
Why?
|
| Pelvis | 4 | 1997 | 730 | 0.200 |
Why?
|
| Cystoscopy | 4 | 2008 | 134 | 0.200 |
Why?
|
| Early Detection of Cancer | 5 | 2016 | 3086 | 0.200 |
Why?
|
| Addison Disease | 1 | 2002 | 48 | 0.200 |
Why?
|
| Internship and Residency | 3 | 2013 | 5789 | 0.200 |
Why?
|
| Curriculum | 2 | 2021 | 3605 | 0.200 |
Why?
|
| Biopsy, Needle | 3 | 2015 | 1641 | 0.200 |
Why?
|
| History, Ancient | 1 | 2021 | 212 | 0.200 |
Why?
|
| Urinary Tract | 2 | 2002 | 309 | 0.200 |
Why?
|
| Rectal Fistula | 1 | 2001 | 73 | 0.190 |
Why?
|
| Psoas Muscles | 1 | 2001 | 71 | 0.190 |
Why?
|
| Cancer Vaccines | 1 | 2008 | 1023 | 0.190 |
Why?
|
| Stents | 3 | 2005 | 3282 | 0.190 |
Why?
|
| Sperm Count | 5 | 2013 | 216 | 0.190 |
Why?
|
| Free Radical Scavengers | 2 | 2001 | 216 | 0.190 |
Why?
|
| Protective Devices | 1 | 2000 | 71 | 0.190 |
Why?
|
| Aging | 2 | 2016 | 8663 | 0.180 |
Why?
|
| Aged | 53 | 2020 | 163284 | 0.180 |
Why?
|
| Intraoperative Complications | 3 | 2005 | 1198 | 0.180 |
Why?
|
| Thromboembolism | 2 | 1997 | 987 | 0.180 |
Why?
|
| Sexuality | 1 | 2021 | 174 | 0.180 |
Why?
|
| Sleep | 1 | 2016 | 4623 | 0.180 |
Why?
|
| Urethral Neoplasms | 2 | 1997 | 40 | 0.170 |
Why?
|
| Fistula | 1 | 2001 | 220 | 0.170 |
Why?
|
| Cholinergic Antagonists | 1 | 2020 | 165 | 0.170 |
Why?
|
| Teaching | 1 | 2007 | 1174 | 0.170 |
Why?
|
| Disclosure | 1 | 2005 | 736 | 0.170 |
Why?
|
| Staff Development | 1 | 2021 | 223 | 0.170 |
Why?
|
| Mitomycin | 3 | 2015 | 259 | 0.170 |
Why?
|
| Female | 64 | 2021 | 380200 | 0.160 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2008 | 1008 | 0.160 |
Why?
|
| Greece | 1 | 2019 | 344 | 0.160 |
Why?
|
| Population Surveillance | 2 | 2014 | 2616 | 0.160 |
Why?
|
| Equipment Design | 7 | 2005 | 3582 | 0.160 |
Why?
|
| Cadmium Chloride | 1 | 1997 | 9 | 0.160 |
Why?
|
| Yeasts | 1 | 1999 | 284 | 0.160 |
Why?
|
| Adrenal Insufficiency | 1 | 2000 | 184 | 0.160 |
Why?
|
| Urinary Catheterization | 1 | 1999 | 202 | 0.160 |
Why?
|
| Cyclins | 1 | 2000 | 603 | 0.150 |
Why?
|
| Forecasting | 4 | 2011 | 2951 | 0.150 |
Why?
|
| Diagnosis, Differential | 5 | 2023 | 12961 | 0.150 |
Why?
|
| Matrix Metalloproteinase 2 | 3 | 2009 | 472 | 0.150 |
Why?
|
| Colic | 1 | 1997 | 42 | 0.150 |
Why?
|
| Doxorubicin | 2 | 2001 | 2234 | 0.150 |
Why?
|
| Hydrogen Peroxide | 1 | 2001 | 730 | 0.150 |
Why?
|
| Postoperative Complications | 11 | 2005 | 15295 | 0.150 |
Why?
|
| Clinical Competence | 1 | 2013 | 4687 | 0.150 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2000 | 369 | 0.150 |
Why?
|
| Vaginal Diseases | 1 | 1998 | 102 | 0.140 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 1996 | 46 | 0.140 |
Why?
|
| Ultrasonography | 10 | 2006 | 5984 | 0.140 |
Why?
|
| Matrix Metalloproteinase 9 | 3 | 2009 | 638 | 0.140 |
Why?
|
| Standard of Care | 1 | 2020 | 564 | 0.140 |
Why?
|
| Insurance, Health | 3 | 2021 | 2494 | 0.140 |
Why?
|
| Testicular Diseases | 2 | 1996 | 71 | 0.140 |
Why?
|
| Cesarean Section | 1 | 2005 | 1365 | 0.140 |
Why?
|
| Sertoli Cells | 1 | 1996 | 49 | 0.140 |
Why?
|
| Ploidies | 2 | 1996 | 281 | 0.140 |
Why?
|
| Genetic Testing | 2 | 2020 | 3444 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 12 | 2002 | 20130 | 0.130 |
Why?
|
| Urinary Retention | 1 | 2016 | 111 | 0.130 |
Why?
|
| Androgen Antagonists | 3 | 2016 | 1377 | 0.130 |
Why?
|
| Cystoscopes | 1 | 1995 | 5 | 0.130 |
Why?
|
| Methyltestosterone | 1 | 1995 | 19 | 0.130 |
Why?
|
| Kidney Diseases | 4 | 1997 | 2148 | 0.130 |
Why?
|
| Fascia | 1 | 1996 | 135 | 0.130 |
Why?
|
| Middle Aged | 56 | 2020 | 213388 | 0.130 |
Why?
|
| Microsurgery | 2 | 1999 | 796 | 0.130 |
Why?
|
| Eosinophilia | 1 | 2000 | 541 | 0.130 |
Why?
|
| Education, Medical, Continuing | 1 | 2021 | 840 | 0.130 |
Why?
|
| Trinucleotide Repeats | 1 | 2016 | 261 | 0.130 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2020 | 454 | 0.130 |
Why?
|
| Electrocoagulation | 1 | 1996 | 158 | 0.130 |
Why?
|
| Markov Chains | 1 | 2018 | 969 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2013 | 11525 | 0.130 |
Why?
|
| Delivery, Obstetric | 1 | 2002 | 906 | 0.130 |
Why?
|
| History, 18th Century | 2 | 2009 | 213 | 0.130 |
Why?
|
| Telomerase | 1 | 2000 | 730 | 0.120 |
Why?
|
| Cost Savings | 1 | 2020 | 925 | 0.120 |
Why?
|
| Neutrophils | 2 | 1997 | 3721 | 0.120 |
Why?
|
| Biological Assay | 1 | 2017 | 652 | 0.120 |
Why?
|
| World War II | 1 | 2015 | 59 | 0.120 |
Why?
|
| Nephrostomy, Percutaneous | 2 | 2005 | 85 | 0.120 |
Why?
|
| Transcription Factors | 1 | 2014 | 12209 | 0.120 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 1584 | 0.120 |
Why?
|
| Prognosis | 13 | 2017 | 29060 | 0.120 |
Why?
|
| Neoplasm Staging | 15 | 2008 | 11031 | 0.120 |
Why?
|
| Lithotripsy | 1 | 1995 | 144 | 0.120 |
Why?
|
| Ureteral Neoplasms | 2 | 2007 | 111 | 0.120 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2015 | 215 | 0.120 |
Why?
|
| Follicle Stimulating Hormone, Human | 1 | 2013 | 25 | 0.120 |
Why?
|
| Palpation | 1 | 1994 | 167 | 0.120 |
Why?
|
| Treatment Outcome | 12 | 2015 | 63115 | 0.120 |
Why?
|
| Male Urogenital Diseases | 1 | 1994 | 48 | 0.120 |
Why?
|
| Antineoplastic Agents | 5 | 2009 | 13695 | 0.120 |
Why?
|
| France | 1 | 2015 | 517 | 0.110 |
Why?
|
| Narcotics | 1 | 1996 | 343 | 0.110 |
Why?
|
| Female Urogenital Diseases | 1 | 1994 | 52 | 0.110 |
Why?
|
| Autoanalysis | 1 | 1992 | 72 | 0.110 |
Why?
|
| Algorithms | 4 | 2007 | 13882 | 0.110 |
Why?
|
| Rete Testis | 1 | 1992 | 9 | 0.110 |
Why?
|
| Educational Status | 1 | 2021 | 2540 | 0.110 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 13988 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 4 | 2018 | 5390 | 0.110 |
Why?
|
| Adrenal Gland Neoplasms | 3 | 2007 | 740 | 0.110 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1996 | 340 | 0.110 |
Why?
|
| Predictive Value of Tests | 12 | 2017 | 15078 | 0.110 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2015 | 692 | 0.110 |
Why?
|
| Adult | 48 | 2017 | 214056 | 0.110 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 1410 | 0.110 |
Why?
|
| Cysts | 1 | 1998 | 678 | 0.110 |
Why?
|
| Cryopreservation | 1 | 1997 | 670 | 0.110 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2018 | 1683 | 0.100 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 1788 | 0.100 |
Why?
|
| Urethral Stricture | 3 | 1995 | 51 | 0.100 |
Why?
|
| Boston | 5 | 2013 | 9312 | 0.100 |
Why?
|
| Thionucleotides | 1 | 1992 | 107 | 0.100 |
Why?
|
| Theophylline | 1 | 1992 | 132 | 0.100 |
Why?
|
| Preoperative Care | 3 | 2006 | 2250 | 0.100 |
Why?
|
| Telemedicine | 2 | 2020 | 2872 | 0.100 |
Why?
|
| Clinical Trials as Topic | 3 | 2020 | 7914 | 0.100 |
Why?
|
| Warfarin | 2 | 1997 | 1497 | 0.100 |
Why?
|
| Pregnancy | 13 | 2007 | 29144 | 0.100 |
Why?
|
| Cell Separation | 2 | 1994 | 1751 | 0.100 |
Why?
|
| Insemination, Artificial | 1 | 1992 | 98 | 0.100 |
Why?
|
| Diagnostic Techniques, Urological | 1 | 2011 | 28 | 0.100 |
Why?
|
| Magnesium Compounds | 1 | 1991 | 3 | 0.100 |
Why?
|
| Specimen Handling | 2 | 1994 | 694 | 0.100 |
Why?
|
| Feasibility Studies | 2 | 2020 | 5077 | 0.100 |
Why?
|
| Incidence | 3 | 2019 | 20950 | 0.100 |
Why?
|
| General Surgery | 1 | 2002 | 1636 | 0.100 |
Why?
|
| Follow-Up Studies | 14 | 2006 | 39052 | 0.100 |
Why?
|
| Ischemic Attack, Transient | 1 | 2016 | 935 | 0.090 |
Why?
|
| Brachytherapy | 1 | 2018 | 1248 | 0.090 |
Why?
|
| Managed Care Programs | 2 | 2009 | 950 | 0.090 |
Why?
|
| Anastomosis, Surgical | 2 | 2006 | 987 | 0.090 |
Why?
|
| Sperm Injections, Intracytoplasmic | 1 | 2011 | 160 | 0.090 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1996 | 501 | 0.090 |
Why?
|
| Private Practice | 1 | 2011 | 154 | 0.090 |
Why?
|
| Collagen | 1 | 1999 | 2688 | 0.090 |
Why?
|
| Economics | 1 | 2011 | 146 | 0.090 |
Why?
|
| Cocaine | 1 | 1996 | 1007 | 0.090 |
Why?
|
| Risk Assessment | 3 | 2019 | 23336 | 0.090 |
Why?
|
| Time Factors | 12 | 2021 | 40077 | 0.090 |
Why?
|
| Animals | 16 | 2023 | 168770 | 0.090 |
Why?
|
| Disease Progression | 4 | 2014 | 13285 | 0.090 |
Why?
|
| DNA, Neoplasm | 1 | 1995 | 1758 | 0.090 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2013 | 1206 | 0.090 |
Why?
|
| Cyclin A | 2 | 2000 | 60 | 0.090 |
Why?
|
| Hospitals | 1 | 2023 | 3954 | 0.090 |
Why?
|
| Disease Susceptibility | 1 | 2016 | 1782 | 0.090 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2022 | 8949 | 0.080 |
Why?
|
| Defensive Medicine | 1 | 2009 | 48 | 0.080 |
Why?
|
| Legislation as Topic | 1 | 2009 | 80 | 0.080 |
Why?
|
| Psoriasis | 1 | 1997 | 902 | 0.080 |
Why?
|
| Cost Control | 1 | 2011 | 624 | 0.080 |
Why?
|
| Retrospective Studies | 15 | 2020 | 77459 | 0.080 |
Why?
|
| Self Disclosure | 1 | 2009 | 251 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 1956 | 0.080 |
Why?
|
| Seminal Vesicles | 1 | 1988 | 101 | 0.080 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 1995 | 934 | 0.080 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2016 | 1524 | 0.080 |
Why?
|
| Cyclic AMP | 1 | 1992 | 1472 | 0.080 |
Why?
|
| Neoplasms | 2 | 2015 | 21693 | 0.080 |
Why?
|
| Body Temperature | 1 | 1991 | 777 | 0.080 |
Why?
|
| Lactoglobulins | 1 | 1987 | 22 | 0.080 |
Why?
|
| Spermatogenesis | 3 | 1994 | 262 | 0.070 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2011 | 780 | 0.070 |
Why?
|
| Cellulose, Oxidized | 1 | 2006 | 12 | 0.070 |
Why?
|
| Ki-67 Antigen | 2 | 2000 | 644 | 0.070 |
Why?
|
| Immunohistochemistry | 3 | 2015 | 11366 | 0.070 |
Why?
|
| Gelatin Sponge, Absorbable | 1 | 2006 | 60 | 0.070 |
Why?
|
| Angiomatosis | 1 | 1986 | 49 | 0.070 |
Why?
|
| Plasmacytoma | 1 | 1987 | 183 | 0.070 |
Why?
|
| Confidentiality | 2 | 2005 | 612 | 0.070 |
Why?
|
| Urinary Bladder Neck Obstruction | 3 | 1996 | 81 | 0.070 |
Why?
|
| Lactoferrin | 1 | 1987 | 97 | 0.070 |
Why?
|
| Research Support as Topic | 1 | 2011 | 705 | 0.070 |
Why?
|
| Expert Testimony | 1 | 2009 | 356 | 0.070 |
Why?
|
| Genomics | 1 | 2022 | 5717 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 2943 | 0.070 |
Why?
|
| Rhabdomyosarcoma | 1 | 1989 | 382 | 0.070 |
Why?
|
| RNA Interference | 1 | 2015 | 2891 | 0.070 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 1987 | 604 | 0.070 |
Why?
|
| Age Factors | 5 | 2017 | 18373 | 0.070 |
Why?
|
| Physicians, Primary Care | 1 | 2012 | 591 | 0.070 |
Why?
|
| Aged, 80 and over | 16 | 2013 | 57776 | 0.070 |
Why?
|
| Risk | 2 | 2016 | 9688 | 0.070 |
Why?
|
| Pain, Postoperative | 3 | 2000 | 1643 | 0.070 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 3505 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 1 | 2011 | 1602 | 0.070 |
Why?
|
| von Hippel-Lindau Disease | 1 | 1986 | 152 | 0.070 |
Why?
|
| Reimbursement Mechanisms | 1 | 2011 | 670 | 0.060 |
Why?
|
| Anesthesia, Local | 1 | 1987 | 275 | 0.060 |
Why?
|
| Ligation | 2 | 1999 | 453 | 0.060 |
Why?
|
| Workload | 1 | 2011 | 849 | 0.060 |
Why?
|
| Risk Factors | 7 | 2022 | 72295 | 0.060 |
Why?
|
| Sensitivity and Specificity | 8 | 2008 | 14723 | 0.060 |
Why?
|
| Hot Temperature | 1 | 1991 | 1355 | 0.060 |
Why?
|
| Liability, Legal | 1 | 2006 | 213 | 0.060 |
Why?
|
| Survival Rate | 4 | 2013 | 12788 | 0.060 |
Why?
|
| Abscess | 1 | 1988 | 607 | 0.060 |
Why?
|
| Transplantation, Autologous | 2 | 2002 | 2124 | 0.060 |
Why?
|
| HTLV-II Infections | 1 | 2003 | 4 | 0.060 |
Why?
|
| Escherichia coli Infections | 1 | 1988 | 532 | 0.060 |
Why?
|
| Paraparesis, Tropical Spastic | 1 | 2003 | 32 | 0.060 |
Why?
|
| Safety | 1 | 2009 | 1186 | 0.060 |
Why?
|
| Supreme Court Decisions | 1 | 2005 | 128 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 4 | 1998 | 1681 | 0.060 |
Why?
|
| Cushing Syndrome | 1 | 2005 | 249 | 0.060 |
Why?
|
| Urinary Diversion | 2 | 1994 | 138 | 0.060 |
Why?
|
| Hemorrhage | 4 | 1990 | 3461 | 0.060 |
Why?
|
| Electronic Health Records | 1 | 2020 | 4468 | 0.060 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 5135 | 0.060 |
Why?
|
| Needles | 2 | 2000 | 449 | 0.060 |
Why?
|
| Fertility | 3 | 1994 | 781 | 0.060 |
Why?
|
| Germ Cells | 2 | 2000 | 631 | 0.050 |
Why?
|
| alpha 1-Antichymotrypsin | 1 | 2002 | 20 | 0.050 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2016 | 1813 | 0.050 |
Why?
|
| Ureteroscopy | 1 | 2004 | 143 | 0.050 |
Why?
|
| Radiography | 5 | 2004 | 7023 | 0.050 |
Why?
|
| Anticoagulants | 1 | 1997 | 4600 | 0.050 |
Why?
|
| Hyperaldosteronism | 1 | 2005 | 240 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2005 | 1107 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2009 | 1904 | 0.050 |
Why?
|
| Mice, Inbred C3H | 2 | 2001 | 964 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 3 | 2000 | 3616 | 0.050 |
Why?
|
| Iron | 2 | 1987 | 1774 | 0.050 |
Why?
|
| Lymphatic Metastasis | 3 | 2006 | 2924 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 3 | 2015 | 6314 | 0.050 |
Why?
|
| ROC Curve | 3 | 2015 | 3527 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 2850 | 0.050 |
Why?
|
| Pubic Bone | 1 | 2000 | 29 | 0.050 |
Why?
|
| Germany | 1 | 2003 | 862 | 0.050 |
Why?
|
| Household Products | 1 | 2000 | 26 | 0.050 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2003 | 336 | 0.050 |
Why?
|
| Ultrasonics | 2 | 1992 | 212 | 0.050 |
Why?
|
| Schools, Medical | 1 | 2008 | 880 | 0.050 |
Why?
|
| Cell Division | 4 | 2003 | 4569 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2006 | 973 | 0.050 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2003 | 332 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2003 | 10943 | 0.050 |
Why?
|
| Interleukin-12 | 1 | 2003 | 580 | 0.050 |
Why?
|
| Needlestick Injuries | 1 | 2000 | 67 | 0.050 |
Why?
|
| Ethoglucid | 1 | 2000 | 1 | 0.050 |
Why?
|
| Methods | 3 | 1994 | 1129 | 0.050 |
Why?
|
| Hospitalization | 1 | 2020 | 10259 | 0.050 |
Why?
|
| Incidental Findings | 1 | 2005 | 689 | 0.050 |
Why?
|
| Kidney Transplantation | 3 | 1999 | 4251 | 0.050 |
Why?
|
| Thiotepa | 1 | 2000 | 66 | 0.050 |
Why?
|
| Patient Selection | 3 | 2010 | 4216 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 3 | 1997 | 8300 | 0.050 |
Why?
|
| Epirubicin | 1 | 2000 | 80 | 0.050 |
Why?
|
| Prosthesis Failure | 1 | 2005 | 1206 | 0.050 |
Why?
|
| Lipid Peroxidation | 1 | 2001 | 270 | 0.050 |
Why?
|
| Urodynamics | 1 | 1982 | 347 | 0.050 |
Why?
|
| Grief | 1 | 2022 | 248 | 0.050 |
Why?
|
| Aortic Aneurysm | 1 | 1984 | 644 | 0.040 |
Why?
|
| Cyclin E | 1 | 2000 | 172 | 0.040 |
Why?
|
| Dissection | 1 | 2001 | 295 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 6621 | 0.040 |
Why?
|
| Disease | 1 | 2005 | 680 | 0.040 |
Why?
|
| Hybridization, Genetic | 1 | 1999 | 109 | 0.040 |
Why?
|
| Wounds, Penetrating | 1 | 2001 | 307 | 0.040 |
Why?
|
| Hydronephrosis | 2 | 1994 | 269 | 0.040 |
Why?
|
| Organ Size | 3 | 2006 | 2251 | 0.040 |
Why?
|
| Rats | 5 | 1997 | 24252 | 0.040 |
Why?
|
| Cohort Studies | 5 | 2018 | 40558 | 0.040 |
Why?
|
| Acute Disease | 3 | 1997 | 7147 | 0.040 |
Why?
|
| Touch | 1 | 2000 | 306 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2009 | 3493 | 0.040 |
Why?
|
| Placenta Accreta | 2 | 1994 | 225 | 0.040 |
Why?
|
| Sutures | 2 | 1993 | 299 | 0.040 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2000 | 221 | 0.040 |
Why?
|
| Iatrogenic Disease | 1 | 2001 | 547 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2008 | 1860 | 0.040 |
Why?
|
| Recurrence | 2 | 2005 | 8340 | 0.040 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2001 | 337 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 15535 | 0.040 |
Why?
|
| Genitalia, Male | 1 | 1997 | 84 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2008 | 2725 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2006 | 3511 | 0.040 |
Why?
|
| Growth Substances | 1 | 1999 | 784 | 0.040 |
Why?
|
| Color | 2 | 2000 | 307 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 1997 | 5692 | 0.040 |
Why?
|
| Child | 3 | 2023 | 77708 | 0.040 |
Why?
|
| Anemia | 1 | 1987 | 1503 | 0.040 |
Why?
|
| Heredity | 1 | 2017 | 154 | 0.040 |
Why?
|
| Mice | 6 | 2016 | 81202 | 0.040 |
Why?
|
| Osmotic Pressure | 2 | 1994 | 151 | 0.040 |
Why?
|
| Feedback | 1 | 2000 | 795 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 1999 | 694 | 0.040 |
Why?
|
| Education, Medical | 1 | 2009 | 1722 | 0.040 |
Why?
|
| Epidermal Growth Factor | 1 | 1999 | 709 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2001 | 1797 | 0.040 |
Why?
|
| Genital Neoplasms, Male | 1 | 1997 | 74 | 0.040 |
Why?
|
| Lymphoma | 1 | 2005 | 1877 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2008 | 9145 | 0.040 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1997 | 424 | 0.040 |
Why?
|
| Tissue Engineering | 1 | 2006 | 1880 | 0.030 |
Why?
|
| Androgen-Binding Protein | 1 | 1996 | 10 | 0.030 |
Why?
|
| Metalloendopeptidases | 1 | 1998 | 396 | 0.030 |
Why?
|
| Lymphokines | 1 | 1999 | 949 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1997 | 821 | 0.030 |
Why?
|
| Medical Records | 1 | 2002 | 1413 | 0.030 |
Why?
|
| Pain | 1 | 2011 | 4987 | 0.030 |
Why?
|
| Butanones | 1 | 1995 | 27 | 0.030 |
Why?
|
| Drug Costs | 1 | 2003 | 1105 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2000 | 1536 | 0.030 |
Why?
|
| Reoperation | 1 | 2005 | 4201 | 0.030 |
Why?
|
| Miniaturization | 1 | 1996 | 164 | 0.030 |
Why?
|
| Torsion Abnormality | 1 | 1996 | 93 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 1999 | 934 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2000 | 4751 | 0.030 |
Why?
|
| Cell Death | 1 | 2001 | 1707 | 0.030 |
Why?
|
| Immunosorbent Techniques | 1 | 1995 | 184 | 0.030 |
Why?
|
| Fibula | 1 | 1997 | 269 | 0.030 |
Why?
|
| Remote Consultation | 1 | 1998 | 238 | 0.030 |
Why?
|
| Research Design | 1 | 2011 | 5986 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 3 | 2000 | 1799 | 0.030 |
Why?
|
| Students, Medical | 1 | 2008 | 1862 | 0.030 |
Why?
|
| Transferrin | 1 | 1996 | 295 | 0.030 |
Why?
|
| Morbidity | 1 | 2000 | 1768 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 1999 | 1730 | 0.030 |
Why?
|
| Dimerization | 2 | 2008 | 895 | 0.030 |
Why?
|
| Nephritis, Interstitial | 1 | 1995 | 154 | 0.030 |
Why?
|
| Reproductive Techniques | 1 | 1994 | 42 | 0.030 |
Why?
|
| Pulse Therapy, Drug | 1 | 2013 | 35 | 0.030 |
Why?
|
| Carcinoma in Situ | 1 | 2000 | 806 | 0.030 |
Why?
|
| Nurses | 1 | 2003 | 2462 | 0.030 |
Why?
|
| Stroke | 1 | 2016 | 9981 | 0.030 |
Why?
|
| Schools | 1 | 2022 | 1433 | 0.030 |
Why?
|
| Abdomen, Acute | 1 | 1994 | 123 | 0.030 |
Why?
|
| Cicatrix | 1 | 1999 | 764 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1997 | 903 | 0.030 |
Why?
|
| Rupture, Spontaneous | 1 | 1994 | 354 | 0.030 |
Why?
|
| Abdomen | 2 | 1999 | 1118 | 0.030 |
Why?
|
| Colitis | 1 | 2002 | 1170 | 0.030 |
Why?
|
| Technology Assessment, Biomedical | 1 | 1996 | 306 | 0.030 |
Why?
|
| Bandages | 1 | 1995 | 266 | 0.030 |
Why?
|
| Nylons | 1 | 1993 | 47 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2005 | 2020 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2000 | 8642 | 0.030 |
Why?
|
| Dextrans | 1 | 1995 | 595 | 0.030 |
Why?
|
| Neoplasm Seeding | 1 | 1993 | 87 | 0.030 |
Why?
|
| Inhibins | 1 | 2013 | 211 | 0.030 |
Why?
|
| Dysgerminoma | 1 | 1992 | 66 | 0.030 |
Why?
|
| Treatment Failure | 2 | 1998 | 2618 | 0.030 |
Why?
|
| Isoenzymes | 1 | 1997 | 1728 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2009 | 5535 | 0.030 |
Why?
|
| Students | 1 | 2022 | 1651 | 0.030 |
Why?
|
| Models, Biological | 1 | 2009 | 9584 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 1420 | 0.030 |
Why?
|
| Rats, Inbred Strains | 2 | 1991 | 2186 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 1999 | 1677 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2003 | 1900 | 0.030 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 1992 | 50 | 0.030 |
Why?
|
| Cell Size | 1 | 1994 | 643 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 1996 | 1401 | 0.030 |
Why?
|
| Malaria | 1 | 2002 | 1239 | 0.030 |
Why?
|
| Skin Transplantation | 2 | 1995 | 1074 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2022 | 2575 | 0.030 |
Why?
|
| Reference Values | 3 | 1997 | 4982 | 0.030 |
Why?
|
| Glycoproteins | 1 | 1999 | 2266 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2000 | 2969 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2000 | 1903 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2011 | 25628 | 0.020 |
Why?
|
| Neoplasm Metastasis | 3 | 1999 | 4851 | 0.020 |
Why?
|
| Radiography, Interventional | 1 | 1998 | 1095 | 0.020 |
Why?
|
| Dilatation, Pathologic | 1 | 1992 | 520 | 0.020 |
Why?
|
| Diarrhea | 1 | 1998 | 1348 | 0.020 |
Why?
|
| Medicaid | 1 | 2003 | 2737 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1996 | 2649 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2007 | 35424 | 0.020 |
Why?
|
| Tissue Donors | 1 | 1999 | 2241 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 1982 | 1876 | 0.020 |
Why?
|
| Cholecystectomy | 1 | 1992 | 395 | 0.020 |
Why?
|
| Computers | 1 | 1992 | 612 | 0.020 |
Why?
|
| Pedigree | 1 | 2017 | 4642 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 1997 | 2216 | 0.020 |
Why?
|
| Teratoma | 1 | 1992 | 395 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 7281 | 0.020 |
Why?
|
| Adenoma | 2 | 1998 | 2174 | 0.020 |
Why?
|
| Rabbits | 1 | 1995 | 4894 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 2005 | 4839 | 0.020 |
Why?
|
| Urinary Bladder Diseases | 1 | 1989 | 166 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 1997 | 3207 | 0.020 |
Why?
|
| Lipocalins | 1 | 2009 | 170 | 0.020 |
Why?
|
| Postoperative Period | 1 | 1994 | 1842 | 0.020 |
Why?
|
| Vas Deferens | 1 | 1988 | 55 | 0.020 |
Why?
|
| Length of Stay | 2 | 1997 | 6311 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2002 | 4042 | 0.020 |
Why?
|
| Acute-Phase Proteins | 1 | 2009 | 262 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 1997 | 1888 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2008 | 149 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2015 | 3689 | 0.020 |
Why?
|
| Prenatal Care | 1 | 1995 | 1092 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 1994 | 788 | 0.020 |
Why?
|
| Vasectomy | 1 | 1988 | 52 | 0.020 |
Why?
|
| Heparin | 1 | 1995 | 1637 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 1991 | 1588 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2004 | 9445 | 0.020 |
Why?
|
| Cell Count | 1 | 1991 | 1856 | 0.020 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2011 | 271 | 0.020 |
Why?
|
| Magnesium | 1 | 1991 | 813 | 0.020 |
Why?
|
| Calcinosis | 1 | 1996 | 1499 | 0.020 |
Why?
|
| Administration, Oral | 1 | 1995 | 3914 | 0.020 |
Why?
|
| Vaginal Neoplasms | 1 | 1988 | 106 | 0.020 |
Why?
|
| Phosphates | 1 | 1991 | 785 | 0.020 |
Why?
|
| Peritoneal Neoplasms | 1 | 1993 | 665 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 1999 | 2530 | 0.020 |
Why?
|
| ADAM Proteins | 1 | 2008 | 243 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2000 | 3966 | 0.020 |
Why?
|
| Hypertension | 1 | 2007 | 8479 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 3556 | 0.020 |
Why?
|
| Autoantibodies | 1 | 1995 | 2036 | 0.020 |
Why?
|
| Carcinoma | 2 | 1996 | 2375 | 0.020 |
Why?
|
| Age Distribution | 2 | 2006 | 2902 | 0.020 |
Why?
|
| Adolescent | 7 | 2003 | 85784 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2008 | 2255 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2008 | 906 | 0.020 |
Why?
|
| Silicones | 1 | 1986 | 250 | 0.020 |
Why?
|
| Prospective Studies | 4 | 2003 | 53291 | 0.020 |
Why?
|
| Genome, Human | 1 | 1999 | 4420 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1997 | 4424 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2007 | 11718 | 0.020 |
Why?
|
| Medicare | 1 | 2003 | 6566 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 1998 | 3706 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1995 | 2282 | 0.020 |
Why?
|
| Hematocrit | 1 | 1986 | 636 | 0.020 |
Why?
|
| Young Adult | 1 | 2011 | 56434 | 0.020 |
Why?
|
| Proteome | 1 | 2015 | 1798 | 0.020 |
Why?
|
| Multivariate Analysis | 4 | 1999 | 12244 | 0.020 |
Why?
|
| Mediastinal Neoplasms | 1 | 1988 | 423 | 0.020 |
Why?
|
| Nitrosourea Compounds | 1 | 1984 | 32 | 0.020 |
Why?
|
| Central Nervous System Diseases | 1 | 1989 | 518 | 0.020 |
Why?
|
| Mitomycins | 1 | 1984 | 47 | 0.020 |
Why?
|
| Ethylnitrosourea | 1 | 1984 | 51 | 0.020 |
Why?
|
| Cell Membrane | 1 | 1994 | 3749 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 1998 | 3020 | 0.010 |
Why?
|
| Mass Screening | 2 | 2015 | 5255 | 0.010 |
Why?
|
| Estrogens | 1 | 1991 | 1566 | 0.010 |
Why?
|
| Genital Neoplasms, Female | 1 | 1989 | 523 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 1998 | 5857 | 0.010 |
Why?
|
| Logistic Models | 1 | 1998 | 13409 | 0.010 |
Why?
|
| Mutagens | 1 | 1984 | 168 | 0.010 |
Why?
|
| Succinate Dehydrogenase | 1 | 1984 | 146 | 0.010 |
Why?
|
| Aspirin | 1 | 1995 | 3283 | 0.010 |
Why?
|
| Anesthesia | 1 | 1994 | 1560 | 0.010 |
Why?
|
| Databases, Factual | 1 | 1998 | 7730 | 0.010 |
Why?
|
| Smoking | 1 | 2000 | 8987 | 0.010 |
Why?
|
| Drainage | 1 | 1988 | 1142 | 0.010 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2008 | 1157 | 0.010 |
Why?
|
| Aorta, Abdominal | 1 | 1984 | 646 | 0.010 |
Why?
|
| Fees, Medical | 1 | 1982 | 117 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 1999 | 12073 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2006 | 2887 | 0.010 |
Why?
|
| Oncogene Proteins v-erbB | 1 | 1999 | 17 | 0.010 |
Why?
|
| Endopeptidases | 1 | 1984 | 772 | 0.010 |
Why?
|
| Phenotype | 1 | 2017 | 16367 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1996 | 19233 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2008 | 21747 | 0.010 |
Why?
|
| Analysis of Variance | 2 | 1998 | 6366 | 0.010 |
Why?
|
| Tuberous Sclerosis | 1 | 1987 | 1029 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2010 | 2265 | 0.010 |
Why?
|
| Mitotic Index | 1 | 1998 | 172 | 0.010 |
Why?
|
| Meiosis | 1 | 2000 | 339 | 0.010 |
Why?
|
| Pressure | 1 | 1982 | 1203 | 0.010 |
Why?
|
| Utilization Review | 1 | 2000 | 392 | 0.010 |
Why?
|
| Gelatinases | 1 | 1998 | 94 | 0.010 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 1998 | 131 | 0.010 |
Why?
|
| Antigens, Nuclear | 1 | 1998 | 192 | 0.010 |
Why?
|
| Disease-Free Survival | 2 | 1998 | 6896 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 1999 | 772 | 0.010 |
Why?
|
| Regression Analysis | 2 | 1998 | 6459 | 0.010 |
Why?
|
| Leucovorin | 1 | 1999 | 628 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 9957 | 0.010 |
Why?
|
| Collagenases | 1 | 1998 | 228 | 0.010 |
Why?
|
| Calcium | 1 | 1991 | 5755 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1999 | 599 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2009 | 4554 | 0.010 |
Why?
|
| Thorax | 1 | 1999 | 547 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1987 | 2948 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 17445 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2000 | 13104 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1998 | 1801 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 2000 | 13814 | 0.010 |
Why?
|
| Operating Rooms | 1 | 1982 | 817 | 0.010 |
Why?
|
| Benzoylarginine Nitroanilide | 1 | 1994 | 2 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 1996 | 460 | 0.010 |
Why?
|
| Leydig Cell Tumor | 1 | 1994 | 25 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1999 | 1619 | 0.010 |
Why?
|
| Infant | 2 | 2003 | 35134 | 0.010 |
Why?
|
| Proportional Hazards Models | 2 | 2000 | 12356 | 0.010 |
Why?
|
| Blood Loss, Surgical | 1 | 1998 | 662 | 0.010 |
Why?
|
| Spectrophotometry | 1 | 1994 | 313 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2000 | 18111 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2003 | 41005 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 1998 | 1802 | 0.010 |
Why?
|
| Cisplatin | 1 | 1999 | 1662 | 0.010 |
Why?
|
| Methotrexate | 1 | 1999 | 1728 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2000 | 5181 | 0.010 |
Why?
|
| Microspheres | 1 | 1995 | 777 | 0.010 |
Why?
|
| Diuretics | 1 | 1995 | 591 | 0.010 |
Why?
|
| Outpatients | 1 | 2000 | 1487 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 1996 | 841 | 0.010 |
Why?
|
| Burkitt Lymphoma | 1 | 1994 | 327 | 0.010 |
Why?
|
| alpha-Fetoproteins | 1 | 1992 | 224 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 1995 | 995 | 0.010 |
Why?
|
| Edema | 1 | 1995 | 789 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1998 | 1533 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1996 | 1771 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1995 | 1851 | 0.010 |
Why?
|
| Chorionic Gonadotropin | 1 | 1992 | 476 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1995 | 1537 | 0.010 |
Why?
|
| Protein Binding | 1 | 2002 | 9384 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1993 | 2086 | 0.010 |
Why?
|
| Cattle | 1 | 1994 | 3922 | 0.010 |
Why?
|
| Ammonia | 1 | 1989 | 239 | 0.000 |
Why?
|
| Placenta Previa | 1 | 1989 | 117 | 0.000 |
Why?
|
| Osmolar Concentration | 1 | 1989 | 683 | 0.000 |
Why?
|
| Epithelial Cells | 1 | 1999 | 3690 | 0.000 |
Why?
|
| Prevalence | 1 | 2003 | 15221 | 0.000 |
Why?
|
| Parity | 1 | 1989 | 929 | 0.000 |
Why?
|
| Renal Dialysis | 1 | 1995 | 1783 | 0.000 |
Why?
|
| Hyponatremia | 1 | 1989 | 298 | 0.000 |
Why?
|
| Flow Cytometry | 1 | 1996 | 5974 | 0.000 |
Why?
|
| Glycine | 1 | 1989 | 671 | 0.000 |
Why?
|
| Proteins | 1 | 2000 | 6100 | 0.000 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2000 | 3922 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 1999 | 13035 | 0.000 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1994 | 1378 | 0.000 |
Why?
|
| Arm | 1 | 1987 | 589 | 0.000 |
Why?
|
| Adrenal Glands | 1 | 1986 | 546 | 0.000 |
Why?
|
| Angiography | 1 | 1989 | 1639 | 0.000 |
Why?
|
| Mice, Inbred ICR | 1 | 1984 | 352 | 0.000 |
Why?
|
| Hyperplasia | 1 | 1986 | 1185 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 1995 | 4561 | 0.000 |
Why?
|
| Cardiovascular Diseases | 1 | 1989 | 15159 | 0.000 |
Why?
|
| Cell Survival | 1 | 1993 | 5882 | 0.000 |
Why?
|
| Syndrome | 1 | 1989 | 3252 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1984 | 2505 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 1993 | 18034 | 0.000 |
Why?
|
| Heart Failure | 1 | 1995 | 10895 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 1998 | 20823 | 0.000 |
Why?
|